RT Book, Section
A1 Mills, Edward J.
A1 Ioannidis, John P. A.
A1 Thorlund, Kristian
A1 Schünemann, Holger J.
A1 Puhan, Milo A.
A1 Guyatt, Gordon
A2 Guyatt, Gordon
A2 Rennie, Drummond
A2 Meade, Maureen O.
A2 Cook, Deborah J.
SR Print(0)
ID 1183877968
T1 Network Meta-analysis
T2 Users' Guides to the Medical Literature: A Manual for Evidence-Based Clinical Practice, 3rd ed
YR 2015
FD 2015
PB McGraw-Hill Education
PP New York, NY
SN 978-0-07-179071-0
LK jamaevidence.mhmedical.com/content.aspx?aid=1183877968
RD 2024/04/25
AB CLINICAL  SCENARIOYour  patient  is  a  45-year-old  woman  who  experiences  frequent  migraine  headaches  that  last  from  4  to  24  hours  and  prevent  her  from  attending  work  or  looking  after  her  children.  She  has  exhausted  efforts  to  manage  the  symptoms  with  nonsteroidal  anti-inflammatory  drugs  and  seeks  additional  treatment.  You  decide  to  recommend  a  triptan  for  the  patient's  migraine  headaches  but  are  wondering  how  to  choose  from  the  7  available  triptans.  You  retrieve  a  network  meta-analysis  (NMA)  that  evaluates  the  different  triptans  among  this  patient  population.1  You  are  not  familiar  with  this  type  of  study,  and  you  wonder  if  there  are  special  issues  to  which  you  should  attend  in  evaluating  its  methods  and  results.